{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T15:04:46Z","timestamp":1788966286450,"version":"build-2803163510"},"reference-count":53,"publisher":"Japanese Circulation Society","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ J"],"published-print":{"date-parts":[[2019,1,25]]},"DOI":"10.1253\/circj.cj-18-0442","type":"journal-article","created":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T22:40:10Z","timestamp":1543531210000},"page":"267-273","source":"Crossref","is-referenced-by-count":38,"title":["ANGPTL3 Inhibitors\u3000\u2015 Their Role in Cardiovascular Disease Through Regulation of Lipid Metabolism \u2015"],"prefix":"10.1253","volume":"83","author":[{"given":"Eleni","family":"Geladari","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Evangelismos General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiota","family":"Tsamadia","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Evangelismos General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia G.","family":"Vallianou","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Evangelismos General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors: Systematic analysis of population health data. <i>Lancet<\/i> 2006; 367: 1747\u20131757.","DOI":"10.1016\/S0140-6736(06)68770-9"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases. Part I: General considerations, the epidemiologic transition, risk factors, and impact of urbanization. <i>Circulation<\/i> 2001; 104: 2746\u20132753.","DOI":"10.1161\/hc4601.099487"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Endo A, Kuroda M, Tanzawa K. Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML236B fungal metabolites, having hypocholesterolemic activity. <i>FEBS Lett<\/i> 1976; 72: 323\u2013326.","DOI":"10.1016\/0014-5793(76)80996-9"},{"key":"4","unstructured":"4. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). <i>Lancet<\/i> 1994; 344: 1383\u20131389."},{"key":"5","unstructured":"5. Phan B, Dayspring T, Toth P. Ezetimibe therapy: Mechanism of action and clinical update. <i>Vasc Health Risk Manag<\/i> 2012; 8: 415\u2013427."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Hammersley D, Signy M. Ezetimibe: An update on its clinical usefulness in specific patient groups. <i>Ther Adv Chronic Dis<\/i> 2017; 8: 4\u201311.","DOI":"10.1177\/2040622316672544"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. <i>N Engl J Med<\/i> 2017; 376: 1713\u20131722.","DOI":"10.1056\/NEJMoa1615664"},{"key":"8","unstructured":"8. Khera AV, Ridker PM. Demystifying HDL cholesterol-A \u201cHuman Knockout\u201d to the rescue? <i>Clin Chem<\/i> 2017; 63: 33\u201336."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Ko KW, Paul A, Ma K, Li L, Chan L. Endothelial lipase modulates HDL but has no effect on atherosclerosis development in apoE\u2212\/\u2212 and LDLR\u2212\/\u2212 mice. <i>J Lipid Res<\/i> 2005; 46: 2586\u20132594.","DOI":"10.1194\/jlr.M500366-JLR200"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women: Heart and Estrogen\/progestin Replacement Study (HERS) Research Group. <i>JAMA<\/i> 1998; 280: 605\u2013613.","DOI":"10.1001\/jama.280.7.605"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Boden WE, Probstfi eld JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. <i>N Engl J Med<\/i> 2011; 365: 2255\u20132267.","DOI":"10.1056\/NEJMoa1107579"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Goldstein JL, Brown MS. A century of cholesterol and coronaries: From plaques to genes to statins. <i>Cell<\/i> 2015; 161: 161\u2013172.","DOI":"10.1016\/j.cell.2015.01.036"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Gusarova V, Alexa CA, Wang Y, Rafique A, Kim JH, Buckler D, et al. ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys. <i>J Lipid Res<\/i> 2015; 56: 1308\u20131317.","DOI":"10.1194\/jlr.M054890"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Romeo S, Pennacchio LA, Fu Y, Boerwinkle E, Tybjaerg-Hansen A, Hobbs HH, et al. Population-based resequencing of ANGPTL4 uncovers variations that reduce triglycerides and increase HDL. <i>Nat Genet<\/i> 2007; 39: 513\u2013516.","DOI":"10.1038\/ng1984"},{"key":"15","unstructured":"15. Romeo S, Yin W, Kozlitina J, Pennacchio LA, Boerwinkle E, Hobbs HH, et al. Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans. <i>J Clin Invest<\/i> 2009; 119: 70\u201379."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Folsom AR, Peacock JM, Demerath E, Boerwinkle E. Variation in ANGPTL4 and risk of coronary heart disease: The Atherosclerosis Risk in Communities Study. <i>Metabolism<\/i> 2008; 57: 1591\u20131596.","DOI":"10.1016\/j.metabol.2008.06.016"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Wang H, Eckel RH. Lipoprotein lipase: From gene to obesity. <i>Am J Physiol Endocrinol Metab<\/i> 2009; 297: E271\u2013E288.","DOI":"10.1152\/ajpendo.90920.2008"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Dewey FE, Gusarova V, O\u2019Dushlaine C, Gottesman O, Trejos J, Hunt C, et al. Inactivating variants in ANGPTL4 and risk of coronary artery disease. <i>N Engl J Med<\/i> 2016; 374: 1123\u20131133.","DOI":"10.1056\/NEJMoa1510926"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Dewey FE, Gusarova V, Dunbar RL, O\u2019Dushlaine C, Schurmann C, Gottesman O, et al. Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease. <i>N Engl J Med<\/i> 2017; 377: 211\u2013221.","DOI":"10.1056\/NEJMoa1612790"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Di Costanzo A, Di Leo E, Noto D, Cefal\u00f9 AB, Minicocci I, Polito L, et al. Clinical and biochemical characteristics of individuals with low cholesterol syndromes: A comparison between familial hypobetalipoproteinemia and familial combined hypolipidemia. <i>J Clin Lipidol<\/i> 2017; 11: 1234\u20131242.","DOI":"10.1016\/j.jacl.2017.06.013"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Stitziel NO, Khera AV, Wang X, Bierhals AJ, Vourakis AC, Sperry AE, et al. ANGPTL3 deficiency and protection against coronary artery disease. <i>J Am Coll Cardiol<\/i> 2017; 69: 2054\u20132063.","DOI":"10.1016\/j.jacc.2017.02.030"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Wang Y, Gusarova V, Banfi S, Gromada J, Cohen JC, Hobbs HH. Inactivation of ANGPTL3 reduces hepatic VLDL-triglyceride secretion. <i>J Lipid Res<\/i> 2015; 56: 1296\u20131307.","DOI":"10.1194\/jlr.M054882"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Musunuru K, Pirruccello JP, Do R, Peloso GM, Guiducci C, Sougnez C, et al. Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. <i>N Engl J Med<\/i> 2010; 363: 2220\u20132227.","DOI":"10.1056\/NEJMoa1002926"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Viney NJ, van Capelleveen JC, Geary RS, Xia S, Tami JA, Yu RZ, et al. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): Two randomised, double-blind, placebo- controlled, dose-ranging trials. <i>Lancet<\/i> 2016; 388: 2239\u20132253.","DOI":"10.1016\/S0140-6736(16)31009-1"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Graham MJ, Viney N, Crooke RM, Tsimikas S. Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans. <i>J Lipid Res<\/i> 2016; 57: 340\u2013351.","DOI":"10.1194\/jlr.R052258"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Tikka A, Jauhiainen M. The role of ANGPTL3 in controlling lipoprotein metabolism. <i>Endocrine<\/i> 2016; 52: 187\u2013193.","DOI":"10.1007\/s12020-015-0838-9"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Wang CS, Hartsuck J, McConathy WJ. Structure and functional properties of lipoprotein lipase. <i>Biochim Biophys Acta<\/i> 1992; 1123: 1\u201317.","DOI":"10.1016\/0005-2760(92)90165-R"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Wong H, Schotz MC. The lipase gene family. <i>J Lipid Res<\/i> 2002; 43: 993\u2013999.","DOI":"10.1194\/jlr.R200007-JLR200"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Braun JE, Severson DL. Regulation of the synthesis, processing and translocation of lipoprotein lipase. <i>Biochem J<\/i> 1992; 287: 337\u2013347.","DOI":"10.1042\/bj2870337"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Hahn PF. Abolishment of alimentary lipemia following injection of heparin. <i>Science<\/i> 1943; 98: 19\u201320.","DOI":"10.1126\/science.98.2531.19"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Meneghetti MCZ, Hughes AJ, Rudd TR, Nader HB, Powell AK, Yates EA, et al. Heparan sulfate and heparin interactions with proteins. <i>J R Soc Interface<\/i> 2015; 12: 20150589.","DOI":"10.1098\/rsif.2015.0589"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Shimamura M, Matsuda M, Kobayashi S, Ando Y, Ono M, Koishi R, et al. Angiopoietin-like protein 3, a hepatic secretory factor, activates lipolysis in adipocytes. <i>Biochem Biophys Res Commun<\/i> 2003; 301: 604\u2013609.","DOI":"10.1016\/S0006-291X(02)03058-9"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Shimamura M, Matsuda M, Yasumo H, Okazaki M, Fujimoto K, Kono K, et al. Angiopoietin-like protein 3 regulates plasma HDL cholesterol through suppression of endothelial lipase. <i>Arterioscler Thromb Vasc Biol<\/i> 2007; 27: 366\u2013372.","DOI":"10.1161\/01.ATV.0000252827.51626.89"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Graham MJ, Lee RG, Brandt TA, Tai LJ, Fu W, Peralta R, et al. Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides. <i>N Engl J Med<\/i> 2017; 377: 222\u2013232.","DOI":"10.1056\/NEJMoa1701329"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Musunuru K, Kathiresan S. Surprises from genetic analyses of lipid risk factors for atherosclerosis. <i>Circ Res<\/i> 2016; 118: 579\u2013585.","DOI":"10.1161\/CIRCRESAHA.115.306398"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Hirata K, Dichek HL, Cioffi JA, Choi SY, Leeper NJ, Quintana L, et al. Cloning of a unique lipase from endothelial cells extends the lipase gene family. <i>J Biol Chem<\/i> 1999; 274: 14170\u201314175.","DOI":"10.1074\/jbc.274.20.14170"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Jaye M, Lynch KJ, Krawiec J, Marchadier D, Maugeais C, Doan K, et al. A novel endothelial-derived lipase that modulates HDL metabolism. <i>Nat Genet<\/i> 1999; 21: 424\u2013428.","DOI":"10.1038\/7766"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK, et al. Plasma HDL cholesterol and risk of myocardial infarction: A mendelian randomisation study. <i>Lancet<\/i> 2012; 380: 572\u2013580.","DOI":"10.1016\/S0140-6736(12)60312-2"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Ando Y, Shimizugawa T, Takeshita S, Ono M, Shimamura M, Koishi R, et al. A decreased expression of angiopoietin-like 3 is protective against atherosclerosis in apoE-deficient mice. <i>J Lipid Res<\/i> 2003; 44: 1216\u20131223.","DOI":"10.1194\/jlr.M300031-JLR200"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Lupo MG, Ferri N. Angiopoietin-like 3 (ANGPTL3) and atherosclerosis: Lipid and non-lipid related effects. <i>J Cardiovasc Dev Dis<\/i> 2018; 5: 39.","DOI":"10.3390\/jcdd5030039"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Xu YX, Redon V, Yu H, Querbes W, Pirruccello J, Liebow A, et al. Role of angiopoietin-like 3 (ANGPTL3) in regulating plasma level of low-density lipoprotein cholesterol. <i>Atherosclerosis<\/i> 2018; 268: 196\u2013206.","DOI":"10.1016\/j.atherosclerosis.2017.08.031"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Gaudet D, Gipe DA, Pordy R, Ahmad Z, Cuchel M, Shah PK, et al. ANGPTL3 inhibition in homozygous familial hypercholesterolemia. <i>N Engl J Med<\/i> 2017; 377: 296\u2013297.","DOI":"10.1056\/NEJMc1705994"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. ANGPTL3 targeting: The power of versatile lipid-lowering [Editorial]. <i>Atherosclerosis<\/i> 2018; 268: 185\u2013187.","DOI":"10.1016\/j.atherosclerosis.2017.10.002"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Agellon LB, Walsh A, Hayek T, Moulin P, Jiang XC, Shelanski SA, et al. Reduced high density lipoprotein cholesterol in human cholesteryl ester transfer protein transgenic mice. <i>J Biol Chem<\/i> 1991; 266: 10796.","DOI":"10.1016\/S0021-9258(18)99088-5"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Shan L, Yu XC, Liu Z, Hu Y, Sturgis LT, Miranda ML, et al. The angiopoietin-like proteins ANGPTL3 and ANGPTL4 inhibit lipoprotein lipase activity through distinct mechanisms. <i>J Biol Chem<\/i> 2009; 284: 1419\u20131424.","DOI":"10.1074\/jbc.M808477200"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Sonnenburg WK, Daiguan Yu, Lee EC, Xiong W, Gololobov G, Key B, et al. GPIHBP1 stabilizes lipoprotein lipase and prevents its inhibition by angiopoietin-like 3 and angiopoietin-like 4. <i>J Lipid Res<\/i> 2009; 50: 2421\u20132429.","DOI":"10.1194\/jlr.M900145-JLR200"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Gaudet D, Gipe D, Hovingh K, Ahmad Z, Cuchel M, Shah P, et al. Safety and efficacy of evinacumab, a monoclonal antibody to ANGPTL3, in patients with homozygous familial hypercholesterolemia: A single-arm, open-label, proof-of-concept study. <i>Atherosclerosis<\/i> 2017; 263: e9.","DOI":"10.1016\/j.atherosclerosis.2017.06.057"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Miller M. Dyslipidemia and cardiovascular risk: The importance of early prevention. <i>Q J Med<\/i> 2009; 102: 657\u2013667.","DOI":"10.1093\/qjmed\/hcp065"},{"key":"49","unstructured":"49. Fodor JG, Frohlich JJ, Genest JJG, Ruth P, McPherson P; for the Working Group on Hypercholesterolemia and Other Dyslipidemias. Recommendations for the management and treatment of dyslipidemia. <i>CMAJ<\/i> 2000; 162: 1441\u20131447."},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Zhang R. The ANGPTL3-4-8 model, a molecular mechanism for triglyceride trafficking. <i>Open Biol<\/i> 2016; 6: 150272.","DOI":"10.1098\/rsob.150272"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51. Alan R. Tall AR. Increasing lipolysis and reducing atherosclerosis. <i>N Engl J Med<\/i> 2017; 377: 280\u2013283.","DOI":"10.1056\/NEJMe1706907"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52. Yuan Y, Zhang L, Cao H, Yang Y, Zheng Y, Yang XJ. Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: Phase 2 randomized trial results. <i>J Lipid Res<\/i> 2016; 57: 706\u2013713.","DOI":"10.1194\/jlr.M066399"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. <i>N Engl J Med<\/i> 2017; 377: 1119\u20131131.","DOI":"10.1056\/NEJMoa1707914"}],"container-title":["Circulation Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/83\/2\/83_CJ-18-0442\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T05:15:48Z","timestamp":1662527748000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/83\/2\/83_CJ-18-0442\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,25]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1253\/circj.cj-18-0442","relation":{},"ISSN":["1346-9843","1347-4820"],"issn-type":[{"value":"1346-9843","type":"print"},{"value":"1347-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,25]]}}}